𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin’s lymphoma

✍ Scribed by Philipp Kiewe; Eckhard Thiel

Publisher
Springer
Year
2010
Tongue
English
Weight
105 KB
Volume
90
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic results in patients with rel
Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation
✍ Felicetto Ferrara; Assunta Viola; Carolina Copia; Ettore Mariano Schiavone; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract Forty patients with relapsed diffuse large B cell lymphoma (DLBCL) autografted in partial response (PR) (__n__ = 23) or in refractory relapse (RR) (__n__ = 17) achieved complete remission (CR) after autologous stem cell transplantation (ASCT). Salvage treatment consisted of ifosphamide,

Paraneoplastic pemphigus in two patients
Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: Significant responses to cyclophosphamide and prednisolone
✍ Hertzberg, Mark S.; Schifter, Mark; Sullivan, John; Stapleton, Karen 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

To the Editor: Semenzato et al. proposed new criteria for large granular lymphocyte (LGL) leukemia because patients with low levels of GL were similar to those with levels greater than 2,000 GL/l [1]. LGL leukemia is a GL proliferative disease often accompanied by pure red cell aplasia (PRCA). T-cel

Long-term responses in patients with rec
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w